TORONTO, May 27, 2011 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign") announced today that it will introduce its latest generation medical
measurement system, the UFIT® TEN-20, at the International Symposium on
Medical Measurements and Applications (MeMeA), being held in Italy by
the Institute of Electrical and Electronics Engineers (IEEE) on May
30-31, 2011. Dr Radu Leca, Biosign's CEO, will speak and demonstrate
the system during the Plenary Session - Invited Lecture "Issues in
Medical Measurement". For further details on the conference, please
Biosign's UFIT® TEN-20 is an online medical system for blood pressure
and blood glucose monitoring. The device measures the pulse at the
wrist through an inflatable cuff and immediately produces blood
pressure and blood glucose measurement results. All measurements are
indirect, noninvasive and passive. The results are stored on Biosign's
servers along with the complete test sample. Readings can be viewed by
care providers on a secure web portal and/or integrated into a
patient's Electronic Health Record. The UFIT® TEN 20 is approved under
ISO-13485 for the non-invasive measurement of blood pressure and blood
glucose, and it also carries the CE Mark.
"The MeMeA conference offers us a unique opportunity to introduce our
technology to professional and academic thought leaders and to gather
their support for our work", stated Dr. Radu Leca, Biosign's CEO.
With more than 400,000 members in over 160 countries, IEEE is the
world's largest professional association dedicated to advancing
technological innovation and excellence for the benefit of humanity.
IEEE and its members inspire a global community through IEEE's highly
cited publications, conferences, technology standards, and professional
and educational activities
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
| Biosign Contact Information || || || || || || |
| Colley Clarke |
Phone: (416) 218-9800 ext. 234
| || || || || || Alan S. Roemer |
The Trout Group
Phone: (646) 378-2945